Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

A barrier that keeps cancer at bay

Activins are proteins involved in a number of important biological functions, including the regulation of the menstrual cycle, cell proliferation, differentiation, apoptosis, metabolism, homeostasis, immune response, wound repair, and endocrine function. 

Activin B is one of the activin proteins.

It binds and activates a receptor called ALK7 - a member of the tumour growth factor beta (TGFß) receptors superfamily.

When activated, ALK7 triggers a domino effect of molecular and biochemical reactions (a "signalling pathway") that result in various changes across the cell.

Now, a team of researchers spearheaded by the lab of Douglas Hanahan at EPFL have found that activin B and ALK7 expressed by cancer cells can form a "barrier" that not only prevents them from forming new tumours, but also from metastasising.

The findings were published in Developmental Cell.

The project was led by Iacovos P. Michael, a former postdoc in Hanahan's lab.

The researchers studied the ALK7 signalling pathway in mice with either pancreatic neuroendocrine tumours or breast cancer.

They found that when the receptor is activated by activin B, cancer cells died via a process called apoptosis.

On the contrary, blocking ALK7 activation allowed cancer cells to evade death and successfully metastasise to various organs, such as the liver, lungs and brain.

And the way by which cancer cells evaded the activin B/ALK7 "barrier" was by either downregulating activin B and/or downregulating ALK7.

"This study enforces the notion that apoptosis is an important barrier of tumourigenesis, and that its evasion by cancer cells is a key hallmark capability of cancer cells during malignancy and metastasis," says Hanahan.

Furthermore, this study also revealed that the presence of ALK7 correlated with prolonged relapse-free survival (longer time for reappearance) of patients with various cancers, including breast cancer.

Notably, comparatively higher levels of ALK7 expression were also associated with a longer period before metastasis became apparent in breast-cancer patients.

This study introduces a heretofore unappreciated role of a protective activin B/ALK7 "barrier", which triggers apoptosis in ALK7-expressing cells that are therefore not ''authorised'' to proliferate in a particular tissue microenvironment bathed in its ligand.

"Elucidating how cancer cells manage to overcome nature's various 'safety checkpoints' to prevent malignancy is an important step towards understanding tumour biology and disease pathogenesis," says Iacovos Michael.

Source: Ecole Polytechnique Fédérale de Lausanne

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation